EXSCIENTIA
27.4.2021 18:32:11 CEST | Business Wire | Press release
Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round. SoftBank Vision Fund 2i led the Series D and was joined by previous round lead investors, Novo Holdings and funds managed by Blackrock. Other investors included Mubadala Investment Company, Farallon Capital, Casdin Capital, GT Healthcare Capital, Marshall Wace, Pivotal bioVenture Partners, Laurion Capital, Hongkou and Bristol-Myers Squibb. In addition, SoftBank is providing an additional $300 million equity commitment that can be drawn at the Company’s discretion.
Exscientia uses AI across its platform from target identification through drug design and patient selection in order to precision engineer new medicines. The Company has advanced the first two fully AI-designed drugs into clinical trials and now has over 20 active programs in its pipeline. Funding from the Series D round will be used to advance Exscientia’s proprietary pipeline through clinical testing as well as to continue expanding the technology platform toward autonomous drug design.
Commenting on the investment, Eric Chen, Managing Partner of SoftBank Investment Advisers, said: “We believe Exscientia’s innovative use of AI to discover and design better quality drugs with greater efficiency has the potential to create important medicines faster than ever before. With the convergence of technology and biology, drug discovery is rapidly evolving in ways that will reshape the industry. The Exscientia team have been leaders in AI-based drug discovery since the field's inception and we believe they will continue shaping its future.”
Exscientia has built and integrated a broad array of AI and experimental technologies to capture and utilize the most patient-relevant data to precision design drugs for multiparameter optimization. The Company’s platform evaluates the target and mechanism through high content phenomics, novel biophysics and deep learning from biological data. That information is then translated into the design of precision drugs through proprietary AI algorithms driven by thousands of models. By remaking the process of drug discovery, Exscientia is also able to reset industry standards for productivity. To date, the Company has been able to advance seven precision designed drugs from project initiation to development candidate in an average time of 12 months.
Andrew Hopkins, CEO of Exscientia added, “All of our investors share Exscientia’s vision to discover better drugs, faster, through AI and automation. Our patient-first AI platform has repeatedly demonstrated its ability to precision design drugs that address patients’ needs. With the Series D completed, the quality and depth of our shareholder base allows us the freedom to continue to scale both our platform and pipeline.”
About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drugs are created. Exscientia’s AI platform has now designed two drugs that are in Phase 1 human clinical trials.
Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.
Exscientia has offices in Oxford, Miami, Osaka and Dundee. For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI .
i As of the date of this press release, SoftBank Group Corp. has made capital contributions to allow investments by SoftBank Vision Fund 2 (“SVF 2”) in certain portfolio companies. The information included herein is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy limited partnership interests in any fund, including SVF 2. SVF 2 has yet to have an external close, and any potential third-party investors shall receive additional information related to any SVF 2 investments prior to closing. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005905/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compvide Announces Commercial Launch of CIMED and Presents New Research at European Meeting on Complement in Human Disease (EMCHD) 202621.10.2026 12:47:00 CEST | Press release
Compvide, Inc. today announced the commercial launch of its CIMED platform. The CIMED-AP, CIMED-LP, and CIMED-CP kits assess the alternative, lectin, and classical complement pathways, respectively, using 50% serum to support testing under more physiological conditions. The commercial launch follows Compvide’s participation in the 20th European Meeting on Complement in Human Disease (EMCHD), held September 1–5, 2026, in Cardiff, Wales. Through a scientific presentation, poster, and exhibition, the company shared research highlighting the importance of assay conditions in evaluating complement activity and the effects of complement-targeting therapies. Unlike conventional assays that often use highly diluted serum, CIMED assays use 50% serum. Research presented by Compvide at EMCHD highlighted how serum dilution can influence measurements of complement inhibition, particularly at lower drug concentrations. These findings underscore the importance of assay conditions when evaluating pote
Forrester’s 2027 Technology And Security Predictions: AI Will Account For 20% Of All Business Technology Spend21.10.2026 10:30:00 CEST | Press release
Technology and security leaders will face mounting pressure to control AI costs, justify infrastructure choices, and manage emerging risks without slowing innovation According to Forrester’s (Nasdaq: FORR) 2027 technology and security predictions, CIOs and CISOs will face growing pressure to realize returns on their AI investments in infrastructure, security, digital sovereignty, and emerging technologies. Additionally, with global technology spending forecasted to reach $6.1 trillion in 2027, technology leaders will need to balance AI governance and control with innovation and business agility. Forrester’s Predictions reports offer forward-looking insights into the trends and signals that empower leaders and their teams to think beyond the conventional and ignite bold ideas for the year ahead. Forrester’s technology and security predictions cover topics including AI, automation and robotics, tech leadership, cloud computing, tech infrastructure and operations, enterprise software, sof
Forrester’s 2027 B2C Marketing, CX, And Digital Predictions: Rising AI Costs Will Force B2C Leaders To Scale Back A Third Of AI Initiatives21.10.2026 10:30:00 CEST | Press release
According to Forrester’s (Nasdaq: FORR) 2027 B2C marketing, customer experience, and digital predictions, rising AI costs will force B2C marketing leaders to scale back a third of AI initiatives. As AI usage grows and martech vendors increasingly adopt usage-based pricing models, every agent interaction, generated asset, and automated workflow becomes a billable event. As a result, leaders will need to make tougher decisions and focus investments on AI initiatives that deliver measurable business value. Forrester’s Predictions reports deliver forward-looking insights into the signals and trends that will shape the year ahead. Forrester’s consumer marketing, CX, and digital business predictions cover topics including B2C marketing, customer experience, consumer behavior, digital commerce, media and advertising, marketing agencies, content and creative, and trust and privacy. Additional highlights from Forrester’s 2027 B2C marketing, CX, and digital predictions include:CX staffing will r
LTM Launches BlueVerse™ ValueMesh™ to Help Enterprises Scale AI Across Oracle Transformations21.10.2026 10:30:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ ValueMesh™, an AI execution fabric designed to help enterprises industrialize AI across the Oracle transformation lifecycle, from strategy and implementation to operations and continuous innovation. BlueVerse™ ValueMesh™ is developed and validated by LTM as part of its Cloud Services expertise. Built on LTM's deep Oracle expertise and BlueVerse™ portfolio, BlueVerse™ ValueMesh™is designed to help enterprises industrialize AI across their Oracle transformation journey. It brings together AI-native delivery, intelligent automation, AI agents, managed services, intelligent business processes, industry solutions, data, and governance in a unified execution model designed to help organizations move beyond fragmented initiatives and isolated pilots and pursue scalable innovation, continuous optimization, and measurable business outcomes across their Oracle estate. At its core, Bl
Forrester’s 2027 B2B Go-To-Market Predictions: AI Agents Will Influence 75% of B2B Purchase Decisions21.10.2026 10:30:00 CEST | Press release
To remain competitive, providers must strengthen customer trust, substantiate value claims, and offer human expertise and guidance According to Forrester’s (Nasdaq: FORR) 2027 B2B go-to-market predictions, business buyers will increasingly deploy AI agents to handle tasks across the buying process, from supplier discovery and information gathering to contract-renewal analysis. While truly autonomous buying will remain concentrated in high-volume, low-risk, and repeatable purchases, the ubiquity of these agents will require providers to ensure that their systems and sellers can respond with speed, accuracy, and consistency. Forrester’s B2B Predictions reports, covering topics including B2B go-to-market strategy, business buyers, and content and creative, offer forward-looking insights to help executives and their teams anticipate change, reduce uncertainty, and make confident decisions ahead of market shifts. Key highlights from the 2027 B2B go-to-market predictions include: Buyers will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom